Deucravacitinib, a treatment for psoriatic arthritis, was found to be more effective compared to a placebo in improving response across all criteria for minimal disease activity in patients with PsA at 16 weeks. A phase 2 trial showed that deucravacitinib led to significant improvements in musculoskeletal manifestations, psoriasis, and overall physical/mental health, with around 24% of patients achieving minimal disease activity. The study, funded by Bristol Myers Squibb, demonstrated that both 6mg and 12mg daily doses of deucravacitinib were equally effective in reducing PsA symptoms and improving patient outcomes. Longer term data from phase 3 studies will provide more insights into the impact of deucravacitinib over time.
Source link
Deucravacitinib superior to placebo for achieving psoriatic arthritis MDA at 16 weeks
